Global CMO/CDMO Market Set for Steady Growth as Biologics Outsourcing and Specialized Manufacturing Drive Demand | Future Market Insights (FMI)

NEWARK, Del., April 14, 2026 /PRNewswire/ -- According to a latest market analysis by Future Market Insights, the global CMO/CDMO market is witnessing consistent expansion as pharmaceutical and biotech companies increasingly outsource development and manufacturing to focus on core competencies amid rising drug complexity and cost pressures. The CMO/CDMO Market was valued at USD 4.02 billion in 2025 and is projected to reach USD 5.46 billion by 2035, growing at a CAGR of 3.1% during the forecast period. Demand is being fueled by strong biologics and biosimilars pipelines, regulatory support for accelerated approvals, and the shift toward flexible, tech-enabled, and sustainable manufacturing solutions.

Quick Stats: CMO/CDMO Market

• Market Size (2025): USD 4.02 Billion
• Market Size (2035): USD 5.46 Billion
• Growth Rate: 3.1% CAGR (2025–2035)
• Top Growth Countries: India (6.6%), China (5.8%), Germany (3.2%)
• Leading Service Segment: Stand-Alone Services (57.2% share in 2025)
• Leading Product Segment: API Substrates (61.3% share in 2025)
• Top Scale of Operations: Commercial

Detailed market forecasts, competitive benchmarking, and service trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-13038

Pricing Trends and Outsourcing Impact

 Procurement decisions in CMO/CDMO services are moving beyond cost-per-batch toward total value across the drug lifecycle. Sponsors now prioritize:

• End-to-end regulatory support and faster time-to-market
• Quality systems, data integrity, and compliance track record
• Flexibility in scale-up and technology transfer
• Sustainability and ESG performance

Advanced CDMOs offering continuous manufacturing, AI-driven process optimization, and single-use technologies are commanding premium positioning while delivering long-term cost efficiencies.

Installed Base and Capacity Expansion Demand

Pharmaceutical companies are increasingly relying on CDMOs for both clinical and commercial-scale production. Key drivers include:

• Tight in-house biomanufacturing capacity
• Rising complexity of biologics, gene therapies, and personalized medicines
• Need for rapid scale-up and tech transfer capabilities
• Preference for modular and flexible manufacturing facilities

New biologics facilities and expansions by leading CDMOs are supporting strong replacement and greenfield demand, especially in Asia-Pacific.